Synthes gets FDA warning on bone void filler use
This article was originally published in Clinica
Synthes has received an FDA warning letter for allegedly promoting two orthopaedic products for unapproved spinal application. The two products in question - the Norian XR Calcium Phosphate Bone Void filler and Norian SRS Bone Void Filler - are not intended to treat vertebral compression fractures, such as are common in patients with osteoarthritis because it is not known whether the products might cause an embolism, the FDA notes.
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.